Characterizing Longitudinal Molecular Changes in ctDNA in Patients with Metastatic Castration-resistant Prostate Cancer - PubMed
4 hours ago
- #AR alterations
- #ctDNA
- #mCRPC
- Study evaluates longitudinal ctDNA changes in metastatic castration-resistant prostate cancer (mCRPC) patients post-treatment.
- Analyzed data from GuardantINFORM, including patients treated with ARPi, PARPi, or taxanes with ctDNA testing before and after treatment.
- Post-ARPi, AR amplification and mutations (L702H, T878A) increased significantly.
- Post-PARPi, HRR gene alterations (ATM, BRCA2) were common, with some decreases post-treatment.
- Post-taxane, alterations in TP53, AR, PIK3CA, and EGFR increased.
- All treatments led to a significant rise in mutation burden (mean increase 2.0-4.2 alterations).
- AR alterations were consistently linked to worse clinical outcomes across all treatment groups.
- Findings suggest potential for personalized treatment strategies based on ctDNA profiling.